These preliminary analyses suggest that the c‐Myc–IRP2 axis contributes to RTN4IP1 elevation, specifically in ESCC (and thyroid cancer), and other mechanisms may be responsible for RTN4IP upregulation in breast cancer, such as promoter methylation and gene amplification. Here, IREB2 is linked to breast carcinoma.